Submit Deal

TCG CROSSOVER

Summary

TCG Crossover is a science-driven investment firm dedicated to advancing disruptive medicines.

Deals Overview

Total Deals6

Valued Deals6

Total Value£ 644 M

Avg. Deal Size£ 107 M

Market Context

Sort

31 Mar 2021|United States|Biotechnology

Target: ENTRADA THERAPEUTICS INC

Bidder: WELLINGTON MANAGEMENT

16 Service Providers

2 Target | 14 Bidder

29 Dealmakers

5 Target | 25 Bidder

£ 84 M

Value

03 May 2021|United States|Biotechnology

Target: AFFINIA THERAPEUTICS

Bidder: CASDIN CAPITAL

13 Service Providers

1 Target | 12 Bidder

15 Dealmakers

3 Target | 12 Bidder

£ 80 M

Value

10 Jun 2021|United States|Biotechnology

Target: SYNTHEKINE

Bidder: JANUS HENDERSON INVESTORS

13 Service Providers

2 Target | 11 Bidder

13 Dealmakers

2 Target | 11 Bidder

£ 75 M

Value

27 Jul 2021|United Kingdom|Biotechnology

Target: ARTIOS PHARMA LIMITED

Bidder: SOLEUS CAPITAL

12 Service Providers

2 Target | 10 Bidder

13 Dealmakers

3 Target | 10 Bidder

£ 110 M

Value

09 Nov 2021|United States|Pharmaceuticals

Target: ARBOR BIOTHECHNOLOGIES

Bidder: TCG CROSSOVER

4 Service Providers

2 Target | 2 Bidder

5 Dealmakers

3 Target | 2 Bidder

£ 159 M

Value

03 Jul 2024|United States|Health Care Services

Target: BEACON THERAPEUTICS

Bidder: SYNCONA LTD

9 Service Providers

3 Target | 6 Bidder

10 Dealmakers

1 Target | 9 Bidder

£ 134 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy